Henry Meds review

Henry Meds uses a self-pay subscription model rather than billing health insurance. Its current weight-management landing page says the subscription includes unlimited access to healthcare providers, prescribed medication, applicable supplies, and shipping. The main GLP-1 page similarly describes one payment covering provider visits, medication, supplies, and ongoing care. That makes the program more bundled than services that charge a membership fee and then bill the prescription separately. The difficulty is that Henry Meds publishes several different price sets. Its landing page advertises oral microdose semaglutide from $99 per month with three months paid upfront. Other displayed prices—from $119 for injectable liraglutide to $234 for oral tirzepatide—generally require a 12-month plan paid in full. Meanwhile, the main treatment page says GLP-1 care starts at $179 per month, and the legal program page lists $179 monthly liraglutide, $297 injectable semaglutide, and $249 sublingual semaglutide. Consumers should therefore treat $99 as a prepaid monthly equivalent, not a month-to-month price. Before authorizing payment, confirm the total upfront charge, renewal interval, medication, duration, cancellation deadline, and refund terms. Henry’s terms say subscriptions automatically renew and partially used periods generally are not refunded.

Henry Meds’ advertised GLP-1 weight-management program is primarily a compounded-medication service. Current offerings shown on its weight-management page include compounded injectable and oral semaglutide, compounded microdose semaglutide options, compounded oral tirzepatide, and compounded injectable liraglutide. Availability and the clinically appropriate option depend on the provider’s assessment. The page does not advertise these preparations as FDA-approved Wegovy, Zepbound, or Saxenda. This distinction matters. Henry Meds explicitly states that compounded GLP-1 preparations do not undergo FDA premarket review or approval and may differ from commercially available FDA-approved products in safety, effectiveness, risks, and side-effect profiles. Although the medication names correspond to drugs found in FDA-approved products, approval of a branded finished product does not make a separately compounded preparation FDA-approved. FDA’s current consumer guidance says unapproved compounded GLP-1 products are not reviewed for safety, effectiveness, or quality before marketing. FDA recommends that compounded drugs be used only when a patient’s medical needs cannot be met by an FDA-approved drug and that prescriptions be filled by a state-licensed pharmacy. Henry says it uses licensed US 503A compounding pharmacies or 503B outsourcing facilities, but consumers should still verify the exact dispensing pharmacy, formulation, ingredients, concentration, and product label for their individual prescription.

The process starts with an online medical questionnaire covering health history and treatment goals. A licensed provider then reviews the information and determines whether treatment is appropriate. Henry Meds says the consultation may occur through asynchronous review or a scheduled one-to-one video visit, depending partly on the patient’s state. A prescription and subscription are created only if the provider approves treatment. After enrollment, Henry advertises secure patient-portal messaging and unlimited access to healthcare providers as part of the subscription. The GLP-1 page describes ongoing care and says a provider will discuss treatment options before prescribing. Medication and applicable injection supplies are shipped to the patient when prescribed. Published shipment intervals differ among Henry’s pages and may also vary by formulation, so they should not be treated as a guaranteed follow-up schedule. The site does not clearly publish a standard cadence for live follow-up appointments, routine laboratory work, dietitian sessions, or proactive clinical check-ins. “Unlimited access” should therefore be understood as access to request help, not necessarily scheduled monthly clinician visits. Before enrolling, ask how refills are authorized, whether follow-ups are asynchronous or live, how quickly clinical messages are answered, when labs are required, and what happens if side effects or a formulation change require a new evaluation. This review does not provide medical or dosing guidance.

First, capture the final checkout page and compare it with Henry Meds’ program-pricing page. Verify the total charge—not just the advertised monthly equivalent—the commitment length, automatic-renewal date, cancellation deadline, and whether the selected option is refundable. Henry’s terms describe automatic renewal, generally non-refundable prescription products and subscription periods, and a non-refundable $30 consultation component after an evaluation results in a prescription. Second, request the exact name and formulation of the proposed medication. Confirm whether it is compounded, the route of administration, all active and added ingredients, concentration, container type, and the name of the dispensing pharmacy. Verify that the pharmacy is licensed to dispense in the patient’s state and whether it operates under section 503A or 503B. FDA specifically warns consumers to obtain a prescription, use a state-licensed pharmacy, and question unclear labels or products presented as equivalent to FDA-approved drugs. Third, confirm current state and product availability. Henry says its pharmacy partners are licensed across all 50 states, but its terms also state that not every product or service is available in every state. Finally, ask what clinician access, labs, supplies, shipment frequency, replacement policy, and follow-up are included. These checks are especially important because federal compounding policy and individual pharmacy availability can change.

Henry Meds may fit self-pay adults who value remote access, want medication and clinician services combined in one subscription, and are comfortable considering a patient-specific compounded preparation after a licensed provider’s review. It also offers oral and injectable choices, which may appeal to consumers who want to discuss alternatives to a standard weekly injection. The prepaid plans could reduce the displayed monthly equivalent for someone who is prepared to commit funds upfront. It is a weaker fit for anyone who specifically wants an FDA-approved branded GLP-1 product with manufacturer packaging and labeling. Henry’s promoted GLP-1 preparations are compounded, and FDA says these products do not receive the same premarket review for safety, effectiveness, and quality. Consumers who expect insurance billing should also look elsewhere: Henry describes the service as self-pay and says it does not submit insurance claims. The program may also be unsuitable for people who need highly transparent month-to-month pricing, guaranteed scheduled follow-ups, or easy partial refunds. The official pages currently show conflicting price structures, while multi-month plans may require substantial upfront payment. State eligibility, the available formulation, and whether a video visit is required must be confirmed individually. Anyone with complex medical needs or who requires coordinated in-person care should discuss appropriate options with their regular licensed clinician rather than relying solely on a remote subscription platform.